Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.
The objective of this study was to evaluate the cost-effectiveness of posaconazole versus fluconazole for the prevention of invasive fungal infections (IFI) in graft-versus-host disease (GVHD) patients in the Netherlands. A decision analytic model was developed based on a double-blind randomized trial that compared posaconazole with fluconazole antifungal prophylaxis in recipients of allogeneic HSCT with GVHD who were receiving immunosuppressive therapy (Ullmann et al., N Engl J Med 356:335-347, 2007). Clinical events were modeled with chance nodes reflecting probabilities of IFIs, IFI-related death, and death from other causes. Data on life expectancy, quality-of-life, medical resource consumption, and costs were obtained from the literature. The total cost with posaconazole amounted to <euro>9,428 (95% uncertainty interval <euro>7,743-11,388), which is <euro>4,566 (<euro>2,460-6,854) more than those with fluconazole. Posaconazole prophylaxis resulted in 0.17 (0.02-0.36) quality adjusted life year (QALY) gained compared to fluconazole prophylaxis, corresponding to an incremental cost effectiveness ratio (ICER) of <euro>26,225 per QALY gained. A scenario analysis demonstrated that at an increased background IFI risk (from 9% to 15%) the ICER was <euro>13,462 per QALY. Given the underlying data and assumptions, posaconazole prophylaxis is expected to be cost-effective relative to fluconazole in recipients of allogeneic HSCT developing GVHD in the Netherlands. The cost-effectiveness of posaconazole depends on the IFI risk, which can vary by hospital.
Jansen
Jeroen P
JP
Mapi Values, 133 Portland Street, Boston, MA 02114, USA. Jeroen.jansen@mapivalues.com
O'Sullivan
Amy K
AK
Lugtenburg
Elly
E
Span
Lambert F R
LF
Janssen
Jeroen J W M
JJ
Stam
Wiro B
WB
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage* / Q000191:economics*; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D008297:Male; D018803:Models, Economic; D009426:Netherlands; D019057:Quality-Adjusted Life Years; D014230:Triazoles / Q000008:administration & dosage* / Q000191:economics*
D014230:Triazoles; C101425:posaconazole; D015725:Fluconazole
N Engl J Med. 1992 Mar 26;326(13):845-51
1542320
Clin Infect Dis. 2003 Jan 1;36(1):9-15
12491195
N Engl J Med. 2007 Jan 25;356(4):348-59
17251531
Biol Blood Marrow Transplant. 2002;8(12):674-82
12523580
Clin Microbiol Infect. 2001;7 Suppl 2:8-24
11525222
N Engl J Med. 2007 Jan 25;356(4):409-11
17251538
Pharmacoeconomics. 2004;22 Suppl 4:5-10
15876007
Lancet Infect Dis. 2005 Dec;5(12):775-85
16310149
Health Econ. 1994 Mar-Apr;3(2):95-104
8044216
Eur J Health Econ. 2005 Mar;6(1):2-7
15700150
Ann Intern Med. 1997 Dec 15;127(12):1080-8
9412310
Cancer. 2005 May 1;103(9):1916-24
15751024
Blood. 1989 Sep;74(4):1428-35
2670000
Clin Infect Dis. 2002 Apr 1;34(7):909-17
11880955
J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i5-i11
16120635
Eur J Haematol. 2008 Dec;81(6):467-74
18754857
Curr Med Res Opin. 2005 Oct;21(10):1535-46
16238893
J Infect Dis. 1995 Jun;171(6):1545-52
7769290
N Engl J Med. 2007 Jan 25;356(4):335-47
17251530
Bone Marrow Transplant. 1997 Apr;19(8):801-8
9134172
Clin Infect Dis. 1999 Aug;29(2):239-44
10476719
Public Health Rep. 1996 May-Jun;111(3):226-35
8643813
Pharmacoeconomics. 2002;20(6):357-66
12052095
Ned Tijdschr Geneeskd. 2004 Mar 6;148(10):480-4
15042895
Bone Marrow Transplant. 1998 Oct;22(8):755-61
9827972